Ulcerative Colitis Resource Center

Ulcerative Colitis Resource Center

April 29, 2020
1 min read
Save

Low risk for de-novo IBD in patients treated with bariatric surgery, weight loss medications

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Gurismran Kochhar headshot
Gursimran S. Kochhar

Patients who are obese and underwent treatment with either bariatric surgery or weight-loss medications compared with persistently obese patients not exposed to either intervention are at lower risk for development of de-novo inflammatory bowel disease, according to study results.

“Our study points to this direction, in patients who underwent weight-loss surgeries and or were on weight loss medications, despite these interventions, if they failed to achieve normal BMI, they were at higher risk of developing IBD compared with patients who were able to achieve the normal BMI after these interventions,” Gursimran S. Kochhar, MD, from the Division of Gastroenterology, Hepatology & Nutrition at the Allegheny Health Network in Pittsburgh told Healio Gastroenterology and Liver Disease.

Kochhar and colleagues used the Explorys database to estimate the prevalence of de-novo IBD among patients treated with bariatric surgery (Roux‐en‐Y gastrojejunostomy, laparoscopic sleeve gastrectomy or gastric banding, n= 60,870) or weight loss medications (orlistat, phentermine/topiramate, lorcaserin, bupropion/naltrexone and liraglutide, n= 193,790) compared with obese control patients (n= 5,021,210) between 1999 and 2018.

Results showed obese patients exposed to bariatric surgery or weight loss medications had a lower prevalence of de-novo IBD compared with patients with persistent obesity who were not exposed to either intervention (7.22 per 1000 patients vs 11.66 per 1000 patients, P < .0001).

“The risk reduction for de‐novo IBD was consistent across bariatric surgeries and weight loss medications with the exception of orlistat which was not associated with a reduction in risk for de‐novo IBD compared with the persistent obese control cohort,” the authors wrote.

“Given the limitations of our data set, it was hard to assess the treatment outcomes of patients with IBD versus non-IBD patients,” he said. “But our findings will help clinicians diagnose IBD in patients with these types of surgeries much earlier and hopefully institute their IBD treatment at an early onset in the disease course.”– by Monica Jaramillo

 

Disclosure: Kochhar reports no relevant financial disclosures. Please see the full study for all other authors’ relevant financial disclosures.